For patients with BRAF V600-mutant melanoma previously treated with or without BRAF inhibitor in combination with or without MEK inhibitor, the objective response rate was 28.4% (77/271) and 44.2% (72/163), 4-year progression-free survival rate was 15.2% (41/271) and 27.8% (45/163), and 4-year overall survival was 26.9% (73/271) and 49.3% (80/163), respectively (47). The gene discussed is MAP2K7; the disease is melanoma.